SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCS -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (22)4/8/2001 8:56:32 PM
From: Mark Bong  Respond to of 78
 
Tuck, Abarelix Depot has the potential to be a blockbuster, but it may fall short. $150MM seems way too low, but $350-500MM seems to be a decent lower range target. The endometriosis indication is the potential blockbuster though. It will just take more time for that to go through clinical trials.

If the April options expiration week is anything like last month, you may have another chance to pick PRCS up on the cheap. We will see, I guess. Good luck. Mark


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News